Cirrhosis morbidity and mortality are rising worldwide, with health disparities affecting minorities, people of low socioeconomic status, and underserved rural communities. This Review addresses inequities in cirrhosis management and liver transplantation, highlighting the immediate necessity for improving health equity.

Immune-checkpoint inhibitors (ICIs) are used widely in cancer treatment but they can cause adverse effects. This Review discusses immune-mediated liver injury from ICIs, summarizes the current knowledge and offers insights regarding patient treatment.

Lymphatic vessels are important for fluid absorption and immune cell transport. This Review discusses the role of the intestinal lymphatic system in transport and inter-organ communication, exploring lipid absorption mechanisms, gut microenvironment influences, immune cell trafficking and intestinal lymphatics as a drug delivery system.

A scientist’s personal journey through breast cancer underscores the urgency for greater empathy in research and healthcare, a patient-centred approach to data dissemination, and more comprehensive, streamlined support for early-career researchers navigating health crises.

With several drugs in use that inhibit the hepatitis B virus polymerases (nucleos(t)ide analogues (or NUCs)), some argue that new direct-acting antiviral drugs, and new NUCs in particular, are not necessary. Here, we make the counter-argument that additional direct-acting antiviral drugs that can potently suppress hepatitis B virus replication, ideally via distinct mechanisms, are still needed and can provide additional therapeutic benefits.

Non-communicable diseases represent the primary cause of mortality and morbidity globally, accounting for 74% of all deaths and more than three-quarters of years lived with disability. Here, we argue that metabolic dysfunction-associated steatotic liver disease should be considered a non-communicable disease.